

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
				Application Number	10/583,280 – Conf. # 2639
				Filing Date	June 16, 2006
				First Named Inventor	Charles Sawyers
				Art Unit	1636
				Examiner Name	Nancy S. Vogel
Sheet	3	of	7	Attorney Docket Number	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>					

C13	Kingsman et al., <i>Gene</i> , 7: 141 (1979).
C14	Tschumper et al., <i>Gene</i> , 10: 157 (1980).
C15	Jones, <i>Genetics</i> , 85:23 (1977).
C16	Feldman, B.J. & Feldman, D. The development of androgen-independent prostate cancer. <i>Nat Rev Cancer</i> 1, 34-45 (2001).
C17	Gelmann, E.P. Molecular biology of the androgen receptor. <i>J Clin Oncol</i> 20, 3001-15 (2002).
C18	Balk, S.P. Androgen receptor as a target in androgen-independent prostate cancer. <i>Urology</i> 60, 132-8; discussion 138-9 (2002).
C19	Taplin, M.E. et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. <i>Cancer Res</i> 59, 2511-5 (1999).
C20	Taplin, M.E. et al. Androgen receptor mutations in androgen-independent prostate cancer: <i>Cancer and Leukemia Group B Study</i> 9663. <i>J Clin Oncol</i> 21, 2673-8 (2003).
C21	Visakorpi, T. et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. <i>Nat Genet</i> 9, 401-6 (1995).
C22	Taplin, M.E. et al. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. <i>N Engl J Med</i> 332, 1393-8 (1995).
C23	Veldscholte, J. et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. <i>Biochem Biophys Res Commun</i> 173, 534-40 (1990).
C24	Matias, P.M. et al. Structural basis for the glucocorticoid response in a mutant human androgen receptor (AR(cc1)) derived from an androgen-independent prostate cancer. <i>J Med Chem</i> 45, 1439-46 (2002).
C25	Craft, N., Shostak, Y., Carey, M. & Sawyers, C.L. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. <i>Nat Med</i> 5, 280-5 (1999).
C26	Gioeli, D. et al. Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. <i>J Biol Chem</i> 277, 29304-14 (2002).
C27	Kato, S. et al. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. <i>Science</i> 270, 1491-4 (1995).
C28	Font de Mora, J. & Brown, M. AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. <i>Mol Cell Biol</i> 20, 5041-7 (2000).
C29	Tremblay, A., Tremblay, G.B., Labrie, F. & Giguere, V. Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1. <i>Mol Cell</i> 3, 513-9 (1999).
C30	Gregory, C.W. et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. <i>Cancer Res</i> 61, 4315-9 (2001).
C31	Li, P. et al. Heterogeneous expression and functions of androgen receptor co-factors in primary prostate cancer. <i>Am J Pathol</i> 161, 1467-74 (2002).
C32	Glass, C.K. & Rosenfeld, M.G. The coregulator exchange in transcriptional functions of nuclear receptors. <i>Genes Dev</i> 14, 121-41 (2000).

Examiner Signature	/Sean Aeder/ (03/29/2010)	Date Considered
--------------------	---------------------------	-----------------